Risk of tighter regulation under the Act on Specified Commercial Transactions
First written in FY2017. 4 of 7 entries say "Restated". Latest entry: FY2023.
The whole theme swung hardest in 2025: 6 of 29 companies on the "Worse" side.
50 other companies' latest entry also says "Restated".
- FY2023RestatedAnnual report
「Because the business activities of the EC operators that are our customers are subject to regulations and rules under the Act on Specified Commercial Transactions (Act on Specified Commercial Transactions), the Act against Unjustifiable Premiums and Misleading Representations (Act against Unjustifiable Premiums and Misleading Representations), the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Pharmaceuticals and Medical Devices Act), and other laws and regulations, our group's business and operating results may be affected if additional legal obligations are imposed in the future.」
The company continues to identify as a risk additional legal obligations under the Act on Specified Commercial Transactions, the Act against Unjustifiable Premiums and Misleading Representations, the Pharmaceuticals and Medical Devices Act and other laws and regulations relevant to customers. - FY2021RestatedAnnual report
「Because the business activities of the EC operators that are our customers are subject to regulations and rules under the Act on Specified Commercial Transactions (Act on Specified Commercial Transactions), the Act against Unjustifiable Premiums and Misleading Representations (Act against Unjustifiable Premiums and Misleading Representations), the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Pharmaceuticals and Medical Devices Act), and other laws and regulations, our business and operating results may be affected if additional legal obligations are imposed in the future.」
The company continues to identify as a risk additional legal obligations under the Act on Specified Commercial Transactions, the Act against Unjustifiable Premiums and Misleading Representations, the Pharmaceuticals and Medical Devices Act and other laws and regulations relevant to customers. - FY2020RestatedAnnual report
「Because the business activities of the EC operators that are our customers are subject to regulations and rules under the Act on Specified Commercial Transactions (Act on Specified Commercial Transactions), the Act against Unjustifiable Premiums and Misleading Representations (Act against Unjustifiable Premiums and Misleading Representations), the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Pharmaceuticals and Medical Devices Act), and other laws and regulations, our business and operating results may be affected if additional legal obligations are imposed in the future.」
The company continues to identify as a risk additional legal obligations under the Act on Specified Commercial Transactions, the Act against Unjustifiable Premiums and Misleading Representations, the Pharmaceuticals and Medical Devices Act and other laws and regulations relevant to customers. - FY2020-Q1MitigatedAnnual report
「Through the acquisition of the イシミル business, we believe that ensuring the sound development of our customers and the subscription-based e-commerce market in which they operate will mitigate risks to our business and operating results and strengthen the growth foundation for achieving the subscription economy ecosystem that we have established as a long-term objective.」
Through the acquisition of the medical article writing and editorial supervision service, the company added a means of reducing customers' legal and reputational risks. - FY2019ReframedAnnual report
「Because the business activities of the EC operators that are our customers are subject to regulations and rules under the Act on Specified Commercial Transactions (Act on Specified Commercial Transactions), the Act against Unjustifiable Premiums and Misleading Representations (Act against Unjustifiable Premiums and Misleading Representations), the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Pharmaceuticals and Medical Devices Act), and other laws and regulations, our business and operating results may be affected if additional legal obligations are imposed in the future.」
The company has reorganized its explanation of laws and regulations relevant to customers from the Act on Specified Commercial Transactions alone to multiple laws, including the Act against Unjustifiable Premiums and Misleading Representations and the Pharmaceuticals and Medical Devices Act. - FY2018RestatedAnnual report
「Because the business activities of the EC operators that are our customers are subject to regulations and rules under the Act on Specified Commercial Transactions, among others, our business and operating results may be affected if additional legal obligations are imposed in the future.」
The company reiterates the risk of additional obligations under the Act on Specified Commercial Transactions applicable to its EC operator customers. - FY2017First statedAnnual report
「Because the business activities of the EC operators that are our customers are subject to regulations and rules under the Act on Specified Commercial Transactions, among others, our business and operating results may be affected if additional legal obligations are imposed in the future.」
The company identifies as a risk additional legal obligations under the Act on Specified Commercial Transactions applicable to its EC operator customers.